Andrea Franson, MD, discusses the mechanism of action of tovorafenib and its emerging role within the evolving treatment paradigm for pLGG.
Andrea Franson, MD
Advertisement
Andrea Franson, MD is a clinical associate professor of pediatrics, fellowship director of Pediatric Hematology/Oncology, and a pediatric oncologist in the Department of Pediatrics at the University of Michigan Medical School.
Articles by Andrea Franson, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5